International Study Shows that Active Surveillance Holds Promise as a Treatment Option for Low-Risk Thyroid Cancer
Results from a new study co-led by researchers at Dartmouth’s Geisel School of Medicine and the Department of Surgery at Kuma Hospital in Kobe, Japan, show that active surveillance can be successfully implemented as a viable treatment option for patients with low-risk thyroid cancer. (Source: News at Dartmouth Medical School)
Source: News at Dartmouth Medical School - December 7, 2020 Category: Hospital Management Authors: Timothy Dean Tags: News Press Release Research The Dartmouth Institute thyroid cancer Source Type: news
Study shows that active surveillance holds promise as a treatment option for low-risk thyroid cancer
(The Geisel School of Medicine at Dartmouth) Results from a new study co-led by researchers at Dartmouth's Geisel School of Medicine and the Department of Surgery at Kuma Hospital in Kobe, Japan, show that active surveillance can be successfully implemented as a viable treatment option for patients with low-risk thyroid cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 7, 2020 Category: Cancer & Oncology Source Type: news
Thyroid cancer symptoms: Do you have a lump on your neck? How to tell it is cancerous
THYROID cancer is a relatively uncommon type of cancer, with there being around 3,700 new thyroid cancer cases in the UK every year. A lump in the neck is one of the main warning signs - but when should you be worried? (Source: Daily Express - Health)
Source: Daily Express - Health - December 4, 2020 Category: Consumer Health News Source Type: news
Roche announces FDA approval of Gavreto (pralsetinib) for people with advanced or metastatic RET-mutant and RET fusion-positive thyroid cancers
Basel, 2 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto ™ (pralsetinib) for the treatment of adult and paediatric patients 12 years of age and older with advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) who require systemic therapy, or with advanced or metastatic RET fusion-positive thyroid cancer who re quire systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). These indications were approved under the FDA’s accelerated approval program...
Source: Roche Media News - December 2, 2020 Category: Pharmaceuticals Source Type: news
Roche announces FDA approval of Gavreto (pralsetinib) for people with advanced or metastatic RET-mutant and RET fusion-positive thyroid cancers
Basel, 2 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto ™ (pralsetinib) for the treatment of adult and paediatric patients 12 years of age and older with advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) who require systemic therapy, or with advanced or metastatic RET fusion-positive thyroid cancer who re quire systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). These indications were approved under the FDA’s accelerated approval program...
Source: Roche Investor Update - December 2, 2020 Category: Pharmaceuticals Source Type: news
FDA approves pralsetinib for RET-altered thyroid cancers
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 1, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Genentech Announces FDA Approval of Gavreto (pralsetinib) for People With Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancers
South San Francisco, CA -- December 1, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto™ (pralsetinib) for the treatment of adult... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 1, 2020 Category: Drugs & Pharmacology Source Type: news
Sussex research points to new effective breast cancer treatment
(Diamond Light Source) An international five-year study led by scientists at the University of Sussex has provided strong evidence for an effective new target for breast cancer treatment. The study, The structure-function relationship of oncogenic LMTK3 being published in Science Advances, involved researchers from seven institutions across three countries including the UKs Diamond Light Source. It suggests LMTK3 inhibitors could be effectively used for treatment of breast cancer, and potentially other types of cancer such as lung, stomach, thyroid and bladder cancer patients (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 13, 2020 Category: Cancer & Oncology Source Type: news
Follow your Endocrine Networks on Twitter
Each of our eight Endocrine Networks now has its own Twitter account, run by the Convenors. Follow them to share news, events, resources, and to keep up to date with your Network colleagues. Get the conversation going in advance of the Network meetings atSfE BES online!The Endocrine Networks are a platform for collaboration between basic and clinical researchers, clinical endocrinologists and endocrine nurses.Go to theMembers' Area to select and update your preferred Networks.Adrenal and Cardiovascular -@adrenalnetwork
Dr Scott MacKenzie& Dr Mick O'Reilly Bone& Cal...
Source: Society for Endocrinology - November 10, 2020 Category: Endocrinology Source Type: news
Thyroid cancer: Lump, swelling and pain in neck are all warning signs to spot
THYROID cancer survival rates are 84 percent for 10 years or more if diagnosed early. Early diagnosis is crucial therefore and spotting the unusual signs could be a matter of life and death. A sign your thyroid cancer has advanced includes these three signs found on your neck. (Source: Daily Express - Health)
Source: Daily Express - Health - November 10, 2020 Category: Consumer Health News Source Type: news
Who's Going to Manage the Thyroid Cancer? Who's Going to Manage the Thyroid Cancer?
Should primary care physicians have a role in managing thyroid cancer patients who require long-term surveillance ? This commentary explores the issue.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 5, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Is Thyroid Cancer Deadly
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - October 27, 2020 Category: General Medicine Source Type: news
Thyroid cancer: Cushing syndrome is a lesser-known warning sign – what is it?
THYROID cancer survival rates are 84 percent for 10 years or more if diagnosed early. Early diagnosis is crucial therefore and spotting the unusual signs could be a matter of life and death. A sign your thyroid cancer has advanced includes Cushing syndrome. What is it? (Source: Daily Express - Health)
Source: Daily Express - Health - October 24, 2020 Category: Consumer Health News Source Type: news
Impact of Overweight and Obesity on Thyroid Cancer Incidence Impact of Overweight and Obesity on Thyroid Cancer Incidence
The incidence of papillary thyroid cancer is on the rise in recent years, as is the prevalence of obesity. Is there a connection?Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 23, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
CMS releases new payment model for radiation oncology
The U.S. Centers for Medicare and Medicaid Services (CMS) today released its...Read more on AuntMinnie.comRelated Reading:
Groups tout value of nuclear medicine to Congress
Expanded Medicaid tied to more thyroid cancer diagnoses
CMS approves payments for Viz.ai software
No need to defer cancer treatment for fear of COVID-19
Radiology's declining reimbursement spans over a decade (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 18, 2020 Category: Radiology Source Type: news
